Vaxcyte Inc

NASDAQ:PCVX  
17.48
-0.28 (-1.58%)
Products

Vaxcyte Announces FDA Clearance Of Investigational New Drug Application For Vax-24 For Prevention Of Invasive Pneumococcal Disease

Published: 01/06/2022 14:15 GMT
Vaxcyte Inc (PCVX) - Vaxcyte Announces FDA Clearance of Investigational New Drug Application for Vax-24 for Prevention of Invasive Pneumococcal Disease.
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for Vax-24 for Prevention of Invasive Pneumococcal Disease.
Expects to Deliver Topline Immunogenicity Results From Phase 1/2 Clinical Study by End of 2022.